BioCryst Pharmaceuticals Inc (BCRX) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

BioCryst Pharmaceuticals Inc (BCRX) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($276.04 Million) in capital expenditures ($802.00K). Check BioCryst Pharmaceuticals Inc (BCRX) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

Data as of

Dec 2025

Most recent filing

BioCryst Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks BioCryst Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see BCRX cash flow conversion.

Annual Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc from 2025 to 2025. See BioCryst Pharmaceuticals Inc (BCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2025	0.01x	$329.88 Million	$2.47 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow